# A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours

> **NCT03658070** · PHASE1 · UNKNOWN · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 34 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumours

## Interventions

- **DRUG:** XY0206

## Key facts

- **NCT ID:** NCT03658070
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-19
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2020-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658070, "A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03658070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*